Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Austrian Post (18/12/2023)

24.12.2023

Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR). In May 2024, an important interim period ends imposing challenging requirements for all medical devices. Products that don’t fulfil these requirements lose their certificate and must not be marketed. Carragelose products fulfil all necessary prerequisites for the MDR and are backed by extensive clinical data, comprising >1000 patients in 12 international clinical trials. Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections. Recent clinical data also support the extension of using Carragelose in Allergy and Eye Care, while the potential of further applications is not yet fully exploited. “MDR-ready products receive a lot of interest from OTC-focused companies. Carragelose products are MDR-ready, which underpins that the time for starting a structured process is right now. It may also become an option in our effort to support the financial stability and flexibility of Marinomed. At the same time, the negotiations for restructuring the debt with the EIB are on the right track. We are still driven by our goal to become profitable in 2024,” Pascal Schmidt, CFO of Marinomed, says. Marinomed Biotech: weekly performance: -4.00%

Austrian Post: The Supervisory Board of Austrian Post appointed Walter Oblin as Chairman of the Management Board and CEO of Austrian Post. The appointment takes effect on 1 October 2024. Walter Oblin has been with the company since 1 October 2009 and has been Chief Financial Officer of Austrian Post since 1 July 2012. On 1 January 2019, he was appointed Deputy Chief Executive Officer and, in addition to his role as Management Board Member responsible for Finance, also took on responsibility for the Mail Division. Walter Oblin will continue in his current role as Management Board Member responsible for Finance and Mail (CFO) until he takes over the position of the Chairman of the Management Board.
Österreichische Post: weekly performance: 2.66%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/12/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Austrian Post (18/12/2023)


24.12.2023, 2504 Zeichen



Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR). In May 2024, an important interim period ends imposing challenging requirements for all medical devices. Products that don’t fulfil these requirements lose their certificate and must not be marketed. Carragelose products fulfil all necessary prerequisites for the MDR and are backed by extensive clinical data, comprising >1000 patients in 12 international clinical trials. Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections. Recent clinical data also support the extension of using Carragelose in Allergy and Eye Care, while the potential of further applications is not yet fully exploited. “MDR-ready products receive a lot of interest from OTC-focused companies. Carragelose products are MDR-ready, which underpins that the time for starting a structured process is right now. It may also become an option in our effort to support the financial stability and flexibility of Marinomed. At the same time, the negotiations for restructuring the debt with the EIB are on the right track. We are still driven by our goal to become profitable in 2024,” Pascal Schmidt, CFO of Marinomed, says. Marinomed Biotech: weekly performance: -4.00%

Austrian Post: The Supervisory Board of Austrian Post appointed Walter Oblin as Chairman of the Management Board and CEO of Austrian Post. The appointment takes effect on 1 October 2024. Walter Oblin has been with the company since 1 October 2009 and has been Chief Financial Officer of Austrian Post since 1 July 2012. On 1 January 2019, he was appointed Deputy Chief Executive Officer and, in addition to his role as Management Board Member responsible for Finance, also took on responsibility for the Mail Division. Walter Oblin will continue in his current role as Management Board Member responsible for Finance and Mail (CFO) until he takes over the position of the Chairman of the Management Board.
Österreichische Post: weekly performance: 2.66%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/12/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #136: Formelaustria Young Driver Programme als Investment, Kart-Talente & Sim-Racer zu F4-Racern machen




 

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, Semperit, Austriacard Holdings AG, Addiko Bank, Immofinanz, Verbund, VIG, CA Immo, Flughafen Wien, Uniqa, AT&S, Cleen Energy, Kostad, Porr, Wolford, Oberbank AG Stamm, UBM, DO&CO, Agrana, Amag, Erste Group, EVN, OMV, Palfinger, Österreichische Post, S Immo, Telekom Austria, Wienerberger, Zalando, SAP.


Random Partner

Montana Aerospace
Montana Aerospace zählt dank ihrer globalen Präsenz in Entwicklung und Fertigung sowie ihrer Multimaterial-Kompetenz zu den weltweit führenden Herstellern von komplexen Leichtbaukomponenten und Strukturen für die Luftfahrtindustrie. Als hochgradig integrierter Komplettanbieter mit State-of-the-Art-Fertigungsstätten in Europa, Amerika und Asien unterstützen wir die Local-to-Local-Strategie unserer Kunden.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten